Trending
Trending
flibanserin
It's exciting for women who have struggled with hypoactive sexual disorder to be recognized and have a medication alternative. Not only is it a viable option for this disruptive sexual dysfunction, but the FDA is showing support in the challenges with female sexual health.
We often joke about low libido, but for many women HSDD is a serious condition. It is up to you and your healthcare professional to determine which protocol is best for your personal health needs.
The controversy about flibanserin is in fact magnificent, and frankly, the entire point. We must talk openly about sexuality and sexual concerns to improve them, personally for one woman at a time, but also uniformly to embrace female sexuality as a vastly larger societal allowance.
Each of us should be allowed to decide whether or not to accept the agency's opinions. Those who want to categorically trust the government would still be able do so. But those who want to rely on other sources would be given the freedom to choose.
WHAT'S HAPPENING
WHAT'S HAPPENING
From a Times editorial, "'Little Pink Pill' for Women Comes With Risks," (NYT, 8/21/15), "The most serious side effects include severely low blood pressure and loss of consciousness."
Since August 18, headlines have proclaimed the news about the approval of the so-called "female Viagra," Addyi™ . The approval sparked enthusiastic responses from advocates and opponents, which will no doubt continue.
Both drugs treat sexual issues, but that's where the similarities end.
Next week, however, we are on track to make the kind of progress in gender equity that usually comes once in a generation. This will be a step forward that makes the battles that came before worth it and, on a personal note, serves as a soothing salve to my chronic outrage.
